文献速递神经免疫

进展独立于复发活动作为复发缓解型多发性硬化试验结局的效用

Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.
PubMed 文献 · Neurology · 2024-12-30

该研究重新分析AFFIRM和SENTINEL两项随机对照试验的个体患者数据,评估进展独立于复发活动(PIRA)和复发相关恶化(RAW)作为试验结局的效用。共纳入2113例参与者,仅8%发生3个月确认的残疾恶化(3M-CDW),其中多数为PIRA(6.8%)而非RAW(0.9%)。PIRA患者中42.2%在第一年随访中有MRI活动,30.9%在第二年有MRI活动。改善事件在整个随访中超过PIRA事件。PIRA和RAW的当前定义不能可靠区分炎症活动导致的残疾恶化与神经变性。

要点

  • 仅8%的参与者发生3M-CDW事件,其中PIRA占6.8%,RAW占0.9%。
  • 42.2%的PIRA患者第一年随访中有MRI活动,30.9%第二年有MRI活动。
  • PIRA和RAW当前定义不能可靠区分炎症活动与神经变性导致的残疾恶化。

核心结论

  • PIRA和RAW的当前定义不能可靠区分复发缓解型多发性硬化中炎症疾病活动与神经变性导致的残疾恶化。
  • PIRA和RAW存在与当前试验结局指标相似的随机变异和测量误差问题。
  • 该分析需要在其他临床数据集中确认;有意义的下一步是在更全面MRI监测的环境中研究PIRA与放射学疾病活动的共存。

研究设计与样本

  • 重新分析AFFIRM(NCT00027300)和SENTINEL(NCT00030966)两项多中心随机对照试验的个体患者数据,比较那他珠单抗与干扰素β或安慰剂在复发缓解型多发性硬化中的疗效,试验访视每3个月一次,持续2年。
  • 共纳入2113例参与者。

主要发现

  • 42.4%的参与者在随访期间出现放射学疾病活动。
  • 仅8%的参与者发生3个月确认的残疾恶化(3M-CDW)事件。
  • 多数3M-CDW事件为PIRA(6.8%)而非RAW(0.9%)。
  • 42.2%的PIRA患者在随访第一年有MRI活动,30.9%在第二年有MRI活动。
  • 改善事件在整个随访中超过PIRA事件,且发生在所有试验组。

局限性

  • 该分析需要在其他临床数据集中确认。
  • 有意义的下一步是在更全面MRI监测的环境中研究PIRA与放射学疾病活动的共存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Progression independent of relapse activity (PIRA) is increasingly used as a measure of disability worsening in multiple sclerosis (MS) and is believed to reflect the more chronic neurodegenerative aspect of MS. However, while conceptually appealing, PIRA and its counterpart relapse-associated worsening (RAW) have not been validated as outcome measures for clinical trials. Here, we study the co-occurrence of MRI activity in patients experiencing PIRA and RAW in a clinical trial setting. To illustrate the problem of random variation and measurement error of these new outcomes, we contrasted PIRA and RAW with similarly defined improvement. METHODS: We reanalyzed individual patient-level data of AFFIRM (NCT00027300) and SENTINEL (NCT00030966), 2 multicenter randomized controlled trials investigating natalizumab compared with interferon beta or placebo in RRMS, with trial visits occurring every 3 months for 2 years. We calculated 3-month-confirmed disability worsening (3M-CDW), RAW, and PIRA events based on worsening on the Expanded Disability Status Scale, 9-hole peg test, or timed 25-foot walk for every trial visit. We related worsening and improvement events to MRI activity throughout follow-up and contrasted worsening of disability with similarly defined improvement. RESULTS: Our analysis included 2,113 participants, 42.4% of whom developed radiologic disease activity during follow-up. Only 8% of participants had a 3M-CDW event. Although the majority of those 3M-CDW events were PIRA (6.8%) and not RAW (0.9%), 42.2% of participants with PIRA had MRI activity in the first year of follow-up and 30.9% in the second. Improvement events exceeded PIRA events throughout follow-up and occurred in all trial arms. Finally, there was no difference in time-to-PIRA between participants with and without radiologic disease activity. DISCUSSION: PIRA and RAW in their current definitions do not reliably distinguish between disability worsening due to inflammatory disease activity and neurodegeneration in RRMS. In addition, PIRA and RAW have similar and troubling issues of random variation and measurement error as currently used trial outcome measures. Our analysis requires confirmation in other clinical data sets; a meaningful next step would be to study the co-occurrence of PIRA with radiologic disease activity in a setting with more comprehensive MRI monitoring.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Strijbis EMM, Mostert J, Comtois J, et al. Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis. Neurology. 2024. PMID: 39960455. doi:10.1212/WNL.0000000000210153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。